Image Source: www.quio.com
The need for injectable treatment monitoring
More accessible injectable therapies are the future of medicine. The direct-to-bloodstream method allows for faster-acting results and opens doors for a wider range of treatments. Today, over 15 million people in America alone are prescribed an injectable therapy.
The primary limitation of injectable therapy can be found in its administration procedure. In most cases, a trained caregiver or medical professional is present to properly administer the syringe. For an infrequent dosage schedule, trips to the clinic or hospital are a minor inconvenience. However, for those abiding by a more vigorous dosage schedule, the constant visits can feel intrusive to one’s day to day life.
The obvious solution is take home injectable therapies to minimize the obstruction to having a normal everyday life. The problem? Placing treatment in the hands of the patient brings about a new set of issues such as proper adherence and usage errors. In America alone, average adherence rates are as low as 50% for injectable therapies and result in over $14B USD of avoidable medical costs as well as $22B USD in lost pharmaceutical revenue.
In comes the Smart Injector
Recognizing the above issues, Alexander Dahmani and Jared Schwartzentruber looked to develop a solution that followed two simple constraints. The first was to work within the existing system by not changing the drug or syringe format as that would lead to slow adoption by pharma and providers as well as require additional FDA involvement. The second was not to burden the patient in efforts to increase adoption and prevent unreliable or inconsistent data collection.
While attending Columbia University, the pair developed their first prototype in Schwartzentruber’s bedroom using a 3D printer. Fast forward to current day, their company, QuiO, now operates out of New Lab in the Brooklyn Navy yard and is eagerly awaiting the production completion of their device, the QuiO Smart Injector One (SI One).
The SI One is the world’s first, real-time, connected drug delivery system for injectable therapies. This IoT-enabled device is capable of administering any syringe based medication with precision and remote monitoring. Ensuring that the full dosage is administered, the device seamlessly uploads usage information to the company’s cloud platform.
In event of error such as partial dose delivery or missed dosage, patients and/or caregivers are notified via automated texts and/or phone calls. To further mitigate possible errors, uploading to the cloud platform requires no smartphone, Wi-Fi, Bluetooth, or application syncing. Using the Smart Injector, patients are able to safely and properly administer treatment at home with the peace of mind that their practitioners can remotely monitor and offer support. Fear of needles? The device even conceals the needle so patients don’t have to watch it going in and out.
Drug Delivery Sensors
Sensors ensure full and proper dosages are delivered. The device is compatible with multiple syringe-based medication formats.
For your own miniature sensor needs, we recommend getting in touch with Yuji Mitsui from Murata on the HWTrek Platform. Murata is a global leader in the development of advanced electronic materials for a variety of industries, including MedTech and healthcare.
The SI One seamlessly uploads data in real-time to the cloud server through a cellular connection which requires no user setup, additional hardware add-ons, Wi-Fi, Bluetooth, or need for application syncing.
Looking to incorporate cellular connectivity to your IoT device? Get in touch with experts Changfu Shi from SIM Technology Group, a leading mobile communication and IoT developer in China, or Joe Ying from Neoway, a global supplier of wireless products and services.
QuiO’s HIPAA-compliant Software Cloud securely stores all patient injection data in real time and detects data inconsistencies or errors using AI-based support capabilities.
Care providers and medical practitioners can access stored data for patient monitoring using the ConnectedRX Care Dashboard. Meanwhile, organizations can track drug performance such as adherence and results utilizing the ConnectedRX Enterprise Dashboard. ConnectedRX also pairs with third-party patient devices such as fitness trackers, scales, and blood pressure cuffs, to provide a total health profile.
The SI One makes at home injection treatment easy and safe. Minimizing the need for frequent clinic and hospital visits, the device addresses the most common mistake of partial dose delivery while still allowing caregivers and medical professionals to monitor patient’s usage practices. With real-time data uploading without the requirement of user input, the SI One can be used by anyone regardless of their tech savviness. The device improves adherence rates and allows for greater adoption of at home injection treatments. With injectable therapies expected to be the future of medicine, it is possible that we will see future cancer patients safely treating themselves at home.